The effects of probiotics and synbiotic supplementation on glucose and insulin metabolism in adults with prediabetes: a double-blind randomized clinical trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE
    • Publication Information:
      Publication: Berlin : Springer Verlag
      Original Publication: Berlin : Springer International, c1991-
    • Subject Terms:
      Blood Glucose/*metabolism ; Diabetes Mellitus, Type 2/*drug therapy ; Insulins/*metabolism ; Prediabetic State/*drug therapy ; Probiotics/*administration & dosage ; Synbiotics/*administration & dosage; Adult ; Aged ; Biomarkers/metabolism ; Diabetes Mellitus, Type 2/metabolism ; Dietary Supplements/analysis ; Double-Blind Method ; Fasting/metabolism ; Female ; Glycated Hemoglobin/metabolism ; Humans ; Insulin Resistance ; Iran ; Male ; Middle Aged ; Prediabetic State/metabolism
    • Abstract:
      Aims: Probiotics and/or prebiotics could be a promising approach to improve metabolic disorders by favorably modifying the gut microbial composition.
      Objectives: To assess the effects of probiotics and synbiotic on glycemic indices in prediabetic individuals who are at risk of type 2 diabetes and its complications.
      Methods: In a double-blind, randomized, placebo-controlled parallel-group clinical trial, 120 prediabetic adults participated and were randomly allocated to receive either probiotics or synbiotic or placebo supplements for 24 weeks. Anthropometric measurements, food record, physical activity and glycemic biomarkers including glycated hemoglobin (HbA1C), fasting plasma glucose (FPG), fasting insulin levels (FIL), homoeostasis model assessment for insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI), and β-cell function (HOMA-B) were assessed at baseline and repeated at 12 and 24 weeks and compared within and between three groups using repeated measure ANOVA.
      Results: Compared with the placebo, synbiotic supplementation resulted in a higher significant reduction in FPG (- 6.5 ± 1.6 vs. - 0.82 ± 1.7 mg/dL, P = 0.01), FIL (- 2.6 ± 0.9 vs. - 0.8 ± 0.8 µIU/mL, P = 0.028), and HOMA-IR (- 0.86 ± 0.3 vs. - 0.16 ± 0.25, P = 0.007), and a significant elevation in the QUICKI (+ 0.01 ± 0.003 vs. + 0.003 ± 0.002, P = 0.006). In addition, significant decreases in HbA1C was seen following the supplementation of probiotics and synbiotic compared with the placebo (- 0.12 ± 0.06 and - 0.14 ± 0.05 vs. +0.07 ± 0.06%, P = 0.005 and 0.008, respectively). HOMA-B was not found to be different between or within the three groups.
      Conclusion: Glycemic improvement by probiotics and particularly synbiotic supplements in prediabetic individuals has been supported by current study. However, further studies are required for optimal recommendations in this important area of patient treatment.
      Trial Registration: Iranian Registry of Clinical Trials: IRCT201511032321N2, Date registered February 27, 2016.
    • Contributed Indexing:
      Keywords: Clinical trial; Prediabetes; Probiotics; Synbiotic
    • Molecular Sequence:
      IRCT IRCT201511032321N2
    • Accession Number:
      0 (Biomarkers)
      0 (Blood Glucose)
      0 (Glycated Hemoglobin A)
      0 (Insulins)
    • Publication Date:
      Date Created: 20180623 Date Completed: 20190506 Latest Revision: 20221207
    • Publication Date:
      20231215
    • Accession Number:
      10.1007/s00592-018-1175-2
    • Accession Number:
      29931423